Chairman's Report
This has been an important year for Phylogica, a period in which our Phylomer technology gained further global recognition as a powerful platform for the discovery of novel peptide-based drug candidates. We have made considerable progress in the advancement of our discovery alliance activities, although falling behind our previous expected time lines for signing new deals. The Company has more active discussions with prospective pharmaceutical and biotechnology partners than at any point in its history and the Board remains committed to its previously stated goals for advancement of existing relationships, signing new partnerships and revenue growth.
The past year has primarily been a period of investment in scaling our screening capabilities and delivery on the goals of our partnered programmes. We have continued to make significant progress in each of the three core elements of our research & development.
To view Report please download PDF below:
